Advanced microbiome therapeutics engineered to produce serotonin in vivo

Morten Otto Alexander Sommer (Inventor), Mareike Bongers (Inventor), Harris He Wang (Inventor), Frank Cusimano (Inventor)

Research output: Patent

44 Downloads (Pure)

Abstract

The invention provides a composition for use as a medicament, comprising cells of a recombinant microorganism capable of producing increased amounts of one or more of 5-hydroxytryptophan (5-HTP), 5-hydroxytryptamine (5-HT) and tryptamine (TRM) as compared to the non-recombinant microorganism from which it was derived. The composition finds use in preventing and/or treating TRM-; 5-HTP-, or 5-HT-related disorders of the central nerve system (CNS); enteric nervous system (ENS); gastro intestine (GI) and metabolism in a mammal, and may be orally administered to a mammal in need thereof. Additionally, a composition comprising cells of a recombinant microorganism capable of producing melatonin is provided for use as a medicament, such as for treatment of depression, dementia, cancer and sleep disorder.

Original languageEnglish
IPCC12N 9/ 88 A I
Patent numberWO2020249784
Filing date12/06/2020
Country/TerritoryInternational Bureau of the World Intellectual Property Organization (WIPO)
Priority date17/07/2019
Priority numberEP20190186680
Publication statusPublished - 17 Dec 2020

Fingerprint

Dive into the research topics of 'Advanced microbiome therapeutics engineered to produce serotonin in vivo'. Together they form a unique fingerprint.

Cite this